INTRODUCrION
Vaccines are generally administered by the subcutaneous or intramuscular route. However, the immune response produced after parenteral administration is inadequate in many instances to ensure optimal host resistance. Many infectious diseases are acquired via the respiratory tree; possibly, the immunizing antigen would be more effective in inducing high-grade host defense if the route of administration were identical to the route of acquisition of the disease. Active immunization against airborne infection by inhalation of living, attenuated microorganisms has been proved with experimental animals and, in some instances, has become routine (1-4, 11-14, 16, 20, 22) . The potential for immunization of man by aerogenic vaccination with single or combined live vaccines has been recognized in the Soviet Union (1) (2) (3) and in the United States (5, 8, 9) . In the Soviet Union, vaccination of man with aerosols of dried, viable tularemia vaccine, singly or in combination with living vaccines of other microorganisms, has received considerable attention. Systemic reactions were reported by Alexsandrov et al. (2) in 2 of 138 volunteers inhaling an estimated 750,000 organisms contained in an aerosol of dried tularemia vaccine.
Kerostovtaev, Onikiyenky, and Khokhlov (17) noted similar complaints in three of eight persons inhaling 7 ,500,000 cells of a comparable product.
Immunity has been measured primarily by serological procedures and by reaction to skin test preparations, but has not been proved by increase in resistance of the vaccinee to challenge with fully virulent organisms. Tigertt (23) has reviewed selected Soviet articles on viable tularemia vaccines, and Lebidinsky (18) has reviewed the published American literature on this subject.
In the United States, live tularemia vaccine prepared from Francisella tularensis strain LVS (live vaccine strain) (7) and administered percutaneously has been proved immunogenic and superior to killed vaccines in studies with volunteers by Saslaw et al. (21) and by McCrumb (19) . Studies by the latter investigator revealed that, although immunized volunteers were protected against challenge by the respiratory route with 200 to 2,000 virulent organisms, resistance could be overcome in about 50% of men when the challenge dose was increased approximately 10-fold. (The genus Francisella, honoring the late Edward Francis of the U.S. Public Health Service and providing better taxonomy, will appear in the next edition of Bergey's Manual.)
In an effort to enhance the immunity provided by LVS, aerogenic vaccination was studied by Eigelsbach et al. (10, 11) Griffith (15) .
Prior to aerosolization of LVS for use as a vaccine in man, all available information pertaining to its safety was evaluated. Extensive experience gained in volunteers and laboratory workers at Fort Detrick by the acupuncture route (8) attested to the attenuation of this strain. Serious reactions, such as secondary pneumonitis or bubo formation, were not seen. Immunogenicity was evident from the excellent protection noted in vaccinated volunteers exposed to aerosol or intracutaneous challenge. The aforementioned thorough animal evaluations suggested that no untoward reactions were likely to occur in man after inhalation of LVS.
Clinical Reactions
Five groups totaling 253 volunteers free from tularemia agglutinins were exposed to aerosolized LVS. The dose ranged from 104 to 108 organisms. Reaction rates correlated directly with size of inoculum. After inhaling a dose of 104 LVS cells, about 30% of 42 volunteers had minor systemic complaints. The majority noted minimal upper respiratory symptoms, such as sore throat or slight cough. Practically all had pea-sized cervical nodes after exposure to aerogenic LVS. None had fever or roentgen evidence of pneumonic infiltration. The signs and symptoms were quite insignificant and would have been overlooked with casual examination or questioning.
A more severe reaction was associated with inhalation of a 108 inoculum. As a result of this massive dose, 90% of the volunteers were symptomatic with headache, coryza, chest pain, and malaise. Actually, they had mild typhoidal tularemia. In 80%, there were temperature elevations of >100 F which occurred on the average at 3 days and lasted an average of 2.5 days. Of 42 men receiving this huge dose, 3 were treated with streptomycin, and several others were put to bed for periods of 2 to 3 days. Chest X rays revealed transient infiltrations in a few of the vaccinees. In general, the reaction just described can be likened to a "flu-like" syndrome. This condition did not incapacitate the majority of volunteers; they were able to con- Conversion rates were reduced and geometric mean agglutinin titers were delayed as the inhaled dose was lowered. After the 104 log dose of LVS, geometric mean titers did not begin to rise significantly until the 3rd week postvaccination, and antibody levels comparable to those associated with acupuncture vaccination occurred between the 4th and 5th weeks (Fig. 1) organisms. This challenge represents approximately 2,500 times the minimum infective dose for man, which has been estimated to be 10 to 50 organisms (21) . This was a severe challenge and probably far exceeds the number encountered during natural exposures. In this experiment, the interval between vaccination and time of challenge did not appear to be a determining factor in the extent of protection. At 2 months 73% of 22 and at 14 months 50% of 32 volunteers exposed developed disease and were treated with antibiotics. (The difference was not significant by the chi square test.) These two groups received the same dose ofaerosolized vaccine. Those men challenged at 4 and 6 months received the two highest doses of LVS (106 and 108), and the subsequent mild vaccine infection may have contributed to the excellent overall resistance of the groups. Table 3 illustrates the significance of the method of vaccination of these volunteers in relation to resistance to respiratory challenge. High-grade protection was acquired by the men inhaling 108 or 106 doses of LVS. A somewhat lower grade protection was observed in man immunized aerogenically with 104 LVS or by acupuncture; similar protection resulted in both groups. The incidence of infection in all four groups of vaccinees was equivalent (60 to 77% had fever of 100 F or greater), but the incidence of the disease was quite different. The 28 infected men in the two groups who had received large doses of LVS by the aerogenic route reacted to the initial infectious process developing from the severe respiratory challenge, but the acquired resistance prevented progression to overt disease requiring specific treatment.
The average incubation period for the control subjects was less by 1 day than that of the vaccinees. The shorter incubation period in the controls plus equal incubation time for all vaccinees, acupuncture as well as aerogenic, suggests that respiratory exposure to LVS did not sensitize the lung parenchyma. If a hypersensitivity reaction had occurred in men vaccinated aerogenically, immediate febrile or systemic reactions might have been expected. No evidence of such reaction was observed. Table 4 presents data accumulated from additional experiments wherein volunteers, immunized by the acupuncture technique, were challenged aerogenically at varying intervals postvaccination. Although the numbers of subjects were small, results were similar to those observed after small-dose aerosol LVS. Immunity waned at about 1 year to the same extent.
Unvaccinated volunteers without demonstrable tularemia agglutinins served as controls in these aerosol challenges. Five of 47 men failed to develop disease. Actually, four men represent these five failures; two were rechallenged and developed pneumonic tularemia, a third was reexposed on two additional occasions before disease was induced, and the fourth has not been rechallenged. Each appeared to be a complete "miss" at time of exposure without subsequent subclinical infection, because antibodies were not demonstrable. Mechanical difficulties, i.e., loose-fitting masks, were implicated as the significant reasons for failure to produce disease and not natural host resistance, because of susceptibility to rechallenge. Similar incidents may also have occurred in the exposed vaccinees. The low frequency of "misses" and presumed equal distribution would not invalidate the per cent protection observed in the challenged vaccinees.
Intradermal Challenge
Small numbers of volunteers receiving vaccine by the respiratory route have been challenged by the intradermal inoculation of 1,000 to 10,000 infectious doses per man of SCHU S4 strain (Table 5) . Protection was excellent. Not only was there no evidence of lessened immunity after 6 months, but also resistance to massive challenges was uniform. The disease rates were comparable to those following challenge of volunteers vaccinated by acupuncture. The clinical appearance of inoculation sites was strikingly different from the lesions in controls. The skin lesion resembled a delayed hypersensitivity reaction in the immune individual; control 
